Mukupera kwa2015, tsvakiridzo yesainzi yakati madhasi evhitamini C akakwira (anenge akaenzana nemaranjisi mazana matatu) anogona kuuraya maseru egomarara remukoloni anotakura akajairika carcinogenic mutation (KRAS neBRAF).
Muna Kurume 2017, magazini ye "Cancer Cell" yakasimbisa kuti zvakachengeteka kugara uchibaya jekiseni 800-1000 nguva inokurudzirwa zuva nezuva yevhitamini C kune varwere vane kenza yehuropi neyemapapu, uye inogona kushandura iron metabolism uye kukonzera chaiyo DNA kukuvara mumaseru ekenza. . Kukonzera kufa kwesero uye kuwana kurapa kunoshanda kwegomarara.
Muna Nyamavhuvhu wegore iroro, zvakaratidzwa mumagazini "Cell" uye "Nature" kuti vhitamini C inogona kudzora kuitika kwehematological tumors uye reverse leukemia nekuita basa reepigenetic modification enzyme (TET2).
Pakutanga kwe2018, mu "Npj-Precision Medical Oncology" sub-journal yeNature, boka rekutsvakurudza reAcademician Wang Hongyang kubva kuEastern Hepatobiliary Surgery Hospital yeNaval Military Medical University yakaunza kufambira mberi kwekutsvakurudza- vhitamini C "kutanga" kuuraya Cancer stem masero egomarara rechiropa uye kugadzirisa kufungidzira kwevarwere .
Zvisinei, chete chiyero chepamusoro chevhitamini C muropa chinowanikwa kuburikidza ne "intravenous administration" yakatsvakurudzwa uye yakasimbiswa kuti ine anti-cancer effect, uye haiwaniki ne "kudya" maranjisi kana mahwendefa evhitamini C. Kana tawana vhitamini C yakawandisa kubva mukudya, muviri unoburitsa vhitamini C yakawandisa kuburikidza nemuweti. Uchiona izvi wakaisa pasi chinyararire orange rainge rakaoma kuisa mumuromo mako? Saka ndapota usawedzera upofu vhitamini C, nekuti haina maturo uye inoparadza mari.
Kunyangwe tsvagiridzo yakasimbisa kuti kubaya vhitamini C kunogona kubatsira kurwisa mamota egomarara rechiropa, usawedzera vhitamini C, haufanire kudya michero yakawandisa ine vhitamini C, uye usashandise mhedzisiro yechikamu chetsvakiridzo chiri pamusoro apa. base, Cherechedza: “Vhitamini C inofanira kuteerera mazano emurapi.
